Hotlist Alert: Big moves in drone logistics, biotech, and more!

In partnership with

& Options Pit

Good day, 360!

Here are some of our top movers today. And please join Jeff Bishop and Olivia Voz for a special rundown of The Game Plan - tonight at 8pm EST for all our 9-5ers! Be the best prepared trader on the Street!

FOCUS LIST🔎

NCEW - Up over 170% in pre after announcing strategic partnership with Soradynamics Inc, introducing an innovative in-vehicle drone logistics system to reshape the last mile delivery in the United States

TOVX - Up over 60% in pre after announcing  primary endpoints for efficacy and safety achieved in VIRAGE Phase 2b clinical trial of VCN-01 with Gemcitabine/nab-Paclitaxel in newly-diagnosed Metastatic pancreatic cancer patients 

PRPL - Up over 20% in pre after reporting financial results, forward guidance

HOTLIST🔥

NCEW - Up over 170% in pre after announcing strategic partnership with Soradynamics Inc, introducing an innovative in-vehicle drone logistics system to reshape the last mile delivery in the United States

New Century Logistics (BVI) Limited (NCEW), through its subsidiaries, provides freight forwarding services in Hong Kong.

In the pre-market this morning, the company announced that it has signed a Memorandum of Understanding (MOU) with Japanese advanced technology company Soradynamics Inc to jointly develop and deploy an innovative in-vehicle drone logistics system ("Micro-Hub System"). This collaboration aims to address the long-standing core pain points of high last-mile delivery costs and labor shortages in the U.S. logistics industry through technological empowerment, driving an efficiency revolution in the sector.

Both parties will combine New Century's global logistics network with Soradynamics's modular technology advantages to develop systems with the following functions:

Intelligent UAV nest design: support automatic take-off and landing of UAV, and seamlessly integrate with the vehicle through sliding structure;

Six-axis robot cooperative operation: realize automatic battery replacement and cargo loading of UAV, reduce the dependence on manual;

Multi-robot collaboration and scalability: support multiple drones to work at the same time.

Shares of NCEW traded up over 170% in the pre-market in reaction to the news.

The $3.90 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $4.50, $5, $6, $6.50, $7 and then the pre-market high at $7,34,

Below 3.90, $3, $2.50 and then a gap fill at $2.23 come into play, with 1.87 below that.

TOVX - Up over 60% in pre after announcing  primary endpoints for efficacy and safety achieved in VIRAGE Phase 2b clinical trial of VCN-01 with Gemcitabine/nab-Paclitaxel in newly-diagnosed Metastatic pancreatic cancer patients 

Theriva Biologics Inc. (TOVX) is a clinical-stage company that develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.

In the pre-market this morning, the company announced positive topline outcomes from the VIRAGE Phase 2b clinical trial evaluating the Company’s lead product candidate VCN-01 (zabilugene almadenorepvec) plus standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) for whom gemcitabine/nab-paclitaxel is the recommended first-line treatment option.

Highlights include:

Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine/nab-paclitaxel SoC 

VCN-01 was well-tolerated, with transient and reversible adverse events (AEs), meeting primary safety endpoint -

Greater differences between the treatment arms were observed in patients receiving 2 doses of VCN-01 -

-Data to be reviewed during a Key Opinion Leader webinar Featuring Dr. Manuel Hidalgo Medina and Dr. Mike Pishvaian on Wednesday May 7th, 2025 at 0800 US EDT 

Shares of TOVX traded up over 60% in the pre-market in reaction to the news:

The $2.47 area has acted as resistance in the pre-market and will be an important level to watch.

Above it, targets to the upside are $2.72 and then the pre-market high at $2.87. Beyond that, $3, $3.60, $4 and $4.20 come into play.

Below $2.47, targets to the downside are $2.08, $2, $1.80, $1.60, a gap fill at $1.36 and then $1.11.

PRPL - Up over 20% in pre after reporting financial results, forward guidance

Purple Innovation Inc. (PRPL) designs, manufactures, and sells sleep and other products in the United States and internationally.

In the after hours yesterday, the company announced results for the first quarter ended March 31, 2025.

Highlights Include:

Exceeded Q1 Adjusted EBITDA Target; Delivered Q1 Sales Consistent with Guidance

GAAP Gross Margin of 39.4% in Q1; Adjusted Gross Margin Above 40% for Fourth Consecutive Quarter

First quarter 2025 net revenue declined by 13.2% to $104.2 million, compared to $120.0 million in the first quarter of 2024, reflecting the impact of persistent macroeconomic challenges and reduced demand in our wholesale and ecommerce channels.

Net loss attributable to Purple Innovation, Inc. for the first quarter was ($19.1) million, an improvement from $(50.2) million in the prior year.

Adjusted EBITDA for the first quarter was $(4.7) million, a significant improvement compared to $(13.2) million last year, driven by ongoing improvements in gross margin and well-managed expenses.

Shares of PRPL traded up  over 20% in the pre-market in reaction to the news:

The $0.85 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $0.90, $0.85, $0.98, $1.06 and then the after-hours high at $1.11. Beyond that $1.20, $1.30 and $1.50 come into play.

Below $0.85, targets to the downside are $0.80, $0.75 and then $0.68.

MARKET NEWS 📰